A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs GSK 2269557 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Jun 2016 Status changed from active, no longer recruiting to completed.
- 25 May 2016 The trial was completed in Netherlands.
- 11 May 2016 Trial status has been completed in Denmark. (Global end date is 25 Apr 2016)